肿瘤抗原肽是新一类肿瘤标志物。肿瘤抗原在细胞体内被分解后
产生的小分子多肽,和MHC I结合形成MHC I-抗原肽复合物后,
表达在癌细胞的表面。该复合物能够被CD8 T细胞识别,因此可以
被利用作为癌细胞的靶分子,可用于诊断和治疗的各个方面,因
此鉴定癌细胞肿瘤抗原肽具有重要的意义。我们发展出了一套综
合了免疫-生物化学化/生物物理-生物信息学方法来鉴定肿瘤抗原
肽的技术平台。细胞学试验表明,鉴定出来的抗原肽能诱导出高度
特异的肿瘤杀伤作用。
技术特点
l 自主知识产权,已授权。(**号:201310439062.2);
l 该方法得到的抗原肽是直接经细胞处理加工的抗原肽,真实有效;
l 抗原肽确定后可刺激CD8T细胞产生有肿瘤杀伤功能的CTL,可用于
细胞治疗;
l 抗原肽所对应抗原可作为肿瘤标志物,用于肿瘤诊断试剂的研发
(抗体诊断、PCR诊断);
l 肿瘤新抗原疫苗的研发。
Tumor antigen peptide identification platform
Tumor antigen peptide is a new class of tumor markers. Tumor antigens
are decomposed in the cell to generate peptides, which bind to MHC-1 to
form MHC-1/antigen peptide complexes, and are displayed on cancer cell
surface. The complexes can be recognized by corresponding CD8 T cells,
and therefore can be used as targets for diagnosis and treatment. Identification
of cancer cell tumor antigen peptides is, therefore, of great importance. We
have developed a technical platform that integrates immune-biochemical /
biophysical-bioinformatics methods to identify tumor antigen peptides. Our
studies on cultured cells have shown that the identified antigenic peptides
can induce a highly specific tumor killing effect.
Technical features and highlights
1. Patented technology involved (patent no. 201310439062.2);
2. The peptides thus obtained are those naturally processed by tumor
celss, therefore authantic and useful;
3. The peptide(s) can be used to stimulate tumor specifc CD8 T cell for
cell immunotherapy;
4. The peptide(s) origing protein(s) can be the tumor marker(s), of potential
use in diagnoisis;
5. Useful in anti-tumor peptide vaccine development.